ArticleDisease markers2022

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.

Shengbin Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.